Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 5 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 4 completed trials have results

Key Signals

Enrollment Performance

Analytics

N/A
2(50.0%)
Early Phase 1
1(25.0%)
Phase 2
1(25.0%)
4Total
N/A(2)
Early Phase 1(1)
Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials
NCT02418533Not ApplicableCompleted

Mono-menotropins Versus rFSH Protocol on Embryo Quality

Role: lead

NCT02793752Completed

Mitochondrial Activity of Cumulus Cells From the Cumulus-oocyte Complex and Oocyte Competence

Role: lead

NCT01946945Phase 2Unknown

Comparison of Standard ART Practice vs. Trophectoderm Biopsy and Whole Chromosome Analysis

Role: collaborator

NCT01669291Not ApplicableCompleted

Effect of GnRH Antagonist vs Agonist Long on IVF Outcome, Peak Estradiol Level,and Duration of Stimulation

Role: lead

NCT01422395Early Phase 1Completed

Effect of Oocyte Vitrification on Fertilization Rate, Embryo Quality and Development

Role: lead

All 5 trials loaded